**Background**
Autoinflammatory diseases are characterized by inappropriate activation of the innate immune system, leading to systemic inflammation and tissue damage. Interleukin-18 (IL-18) is a potent pro-inflammatory cytokine that plays a critical role in the pathogenesis of various inflammatory conditions, including Adult-Onset Still’s Disease (AOSD) and atopic dermatitis. By triggering the production of interferon-gamma (IFN-γ) and other chemokines, IL-18 contributes to the chronic inflammatory cycle observed in these disorders. Consequently, targeting the IL-18 pathway has emerged as a promising therapeutic strategy to mitigate systemic inflammation and improve patient outcomes. In this context, we will introduce a fully human monoclonal antibody targeting IL-18 – Camoteskimab.
**Definition**
Camoteskimab is a fully human IgG1 kappa monoclonal antibody with high affinity for IL-18, exhibiting a binding affinity of 63 pM.
**In Vitro Studies**
According to the Camoteskimab description, this antibody is designed to neutralize the activity of IL-18 and inhibit the formation of the active IL-18/Ra/RB complex. In Camoteskimab In Vitro assays using PBMCs, the antibody potently neutralizes IL-18 activity with an IC50 in the sub-nanomolar range. Furthermore, the Camoteskimab biological activity has been validated through binding assays; immobilized human IL-18 protein binds to Camoteskimab with an EC50 of 201.8 ng/mL. Flow cytometric analysis using A431 cells further confirms its efficacy, where cells stained with the primary antibody at a 1/200 dilution showed significant binding compared to the Human IgG1 kappa isotype control. For researchers seeking detailed experimental parameters, the Camoteskimab protocol provides guidance on reconstitution using sterile PBS or saline. In conclusion, Camoteskimab is a high-affinity neutralizing antibody that serves as a powerful tool for studying the role of IL-18 in autoinflammatory diseases.
Keywords
Camoteskimab, 2492472-82-7, AVTX-007, CERC-007, MEDI 2338, AVTX007, AVTX 007, CERC007, CERC 007, MEDI2338, MEDI-2338, Interleukin Related, IL
References
[1] Bindoli S, et al. Adult-Onset Still’s Disease (AOSD): Advances in Understanding Pathophysiology, Genetics and Emerging Treatment Options. Drugs. 2024;84(3):257-274.
[2] Chen X, et al. Identification of cross-talk pathways and PANoptosis-related genes in periodontitis and Alzheimer’s disease by bioinformatics analysis and machine learning. Front Aging Neurosci. 2024 Aug 27;16:1430290.
[3] Richard Brown, et al. Anti-il-18 antibody therapy for treating atopic dermatitis. WO2024261470A1. 2025-12-20.
[4] Galozzi P, et al. Progress in Biological Therapies for Adult-Onset Still’s Disease. Biologics. 2022;16:21-34. Published 2022 Apr 21.